LineaRx

‘Linear DNA’ combo shows punch in cancer fight

By GREGORY ZELLER // Mark another impressive victory for LineaRX, this time in a two-front battle against cancer. The Stony Brook-based biotech with innovation in its DNA (literally) has lent its unique DNA-sequencing technology to two vaccine-candidate tests run by Italian R&D company Takis Biotech, which is hot on the trail of new therapeutic cancer vaccines. It might be catching up. On Thursday, LineaRX announced that both vaccines – each produced in “linear DNA” form…


For Applied DNA, new blood – and a shot in the arm

By GREGORY ZELLER // Just 11 months after spinning off from its parent company, a Stony Brook startup with expansion in its DNA has made its first corporate acquisition. LineaRX, a subsidiary of Applied DNA Sciences, has acquired the physical assets and intellectual property of Vitatex Inc., a private biotech with close ties to Stony Brook University and a patented method of isolating Invasive Circulating Tumor Cells in standard blood samples – spotting metastatic cells…


No. 349: Canada’s new high, Sikes’ new heights and LineaRX’s highest hopes (plus, repainting President Trump)

  Middle ground: Welcome to Wednesday, dear readers, and the halfway point of another exciting week of socioeconomic innovation. October 17 is in full swing, marking the 25th anniversary of the International Day for the Eradication of Poverty, a U.N. General Assembly effort to address shortages of basic necessities (i.e.: food, clothing, shelter) around the globe and reinforce the notion that poverty and human-rights abuses routinely coexist. Learn more here. Eye of the beholder: On…


At LineaRX, putting the horsepower behind the CAR T

By GREGORY ZELLER // Marking a big step in the war against cancer, a Stony Brook-based startup has initiated pre-clinical development of a non-viral, plasmid-free chimeric antigen receptor modified T-cell manufacturing platform. In English: A novel platform designed to develop and manufacture new pharmaceutical treatments, including treatments for different forms of cancer. The tech comes from LineaRx Inc., a wholly owned subsidiary that officially spun off from Stony Brook-based Applied DNA Sciences in September. Noting…


With new spinoff, biotech goes all-in on DNA sales

By GREGORY ZELLER // A Stony Brook biotech with a growing international reputation for supply-chain security has spun off a new company focused on DNA modification and production. Stony Brook-based Applied DNA Sciences on Tuesday announced the formation of LineaRx Inc., a wholly owned subsidiary that will concentrate on commercializing the parent company’s extensive experience in the design, manufacture and chemical modification of DNA by large-scale polymerase chain reaction – big news for scientists working…